Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Pharmacodynamics of Caplacizumab in Healthy Volunteers and Phase 2/3 Trial Patients with Immune-mediated Thrombotic Thrombocytopenic Purpura.
Journal: Thrombosis and haemostasis
Published: July 15, 2026
Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: December 09, 2025
Challenges and Opportunities in Post-Marketing Reporting of Factor VIII Inhibitors With Efanesoctocog Alfa.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: July 28, 2025
Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial.
Journal: Journal of thrombosis and haemostasis : JTH
Published: February 06, 2025
Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.
Journal: The New England journal of medicine
Published: July 17, 2024
Complex immunogenicity assessment in caplacizumab-treated patients with immune-mediated thrombotic thrombocytopenic purpura who have received plasma exchange.
Journal: Research and practice in thrombosis and haemostasis
Published: May 02, 2024
Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura.
Journal: Research and practice in thrombosis and haemostasis
Published: March 19, 2024
Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study.
Journal: Journal of thrombosis and haemostasis : JTH
Published: March 29, 2022
Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B.
Journal: Blood advances
Published: December 22, 2020
Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic.
Journal: Journal of blood medicine
Published: December 05, 2018
Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study.
Journal: British journal of haematology
Published: October 30, 2018
Last Updated: 09/26/2026